Skip to main content

Publisher: Wiley-Blackwell

Volume 12, Number 6, June 2010

Diabesity: therapeutic options
pp. 463-473(11)
Author: Colagiuri, S.

Favourites:
ADD
Favourites:
ADD

Assessing the cardio–cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
pp. 485-494(10)
Authors: Schweizer, A.; Dejager, S.; Foley, J. E.; Couturier, A.; Ligueros-Saylan, M.; Kothny, W.

Favourites:
ADD

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
pp. 510-516(7)
Authors: Zhang, L.; Feng, Y.; List, J.; Kasichayanula, S.; Pfister, M.

Favourites:
ADD

A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes
pp. 517-531(15)
Authors: Kipnes, M. S.; Hollander, P.; Fujioka, K.; Gantz, I.; Seck, T.; Erondu, N.; Shentu, Y.; Lu, K.; Suryawanshi, S.; Chou, M.; Johnson-Levonas, A. O.; Heymsfield, S. B.; Shapiro, D.; Kaufman, K. D.; Amatruda, J. M.

Favourites:
ADD

Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain
pp. 545-547(3)
Authors: Belanoff, J. K.; Blasey, C. M.; Clark, R. D.; Roe, R. L.

Favourites:
ADD

Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study
pp. 548-551(4)
Authors: Pencek, R.; Roddy, T.; Peters, Y.; De Young, M. B.; Herrmann, K.; Meller, L.; Nguyen, H.; Chen, S.; Lutz, K.

Favourites:
ADD

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more